Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.57 |
| ▸ | MTOR | P42345 | 3/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 5/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328438 | 0.85 | MEN1 (0.45) | MEN1KMT2AEPHX2MTORFPR2 | |
| SCHEMBL23329071 | 0.84 | MEN1 (0.61) | MEN1KMT2AEPHX2MTORCA12 | |
| SCHEMBL23328370 | 0.83 | MEN1 (0.60) | MEN1KMT2AEPHX2MTORFPR2 | |
| SCHEMBL23328365 | 0.82 | FPR2 (0.67) | MEN1KMT2AEPHX2MTORFPR2 | |
| SCHEMBL23328728 | 0.81 | RAB9A (0.53) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL23329078 | 0.81 | SAE1 (0.56) | MEN1KMT2AFPR2CA12CA1 | |
| SCHEMBL23328675 | 0.79 | MAPT (0.56) | MEN1KMT2ACA12CA1CA2 | |
| SCHEMBL23329072 | 0.78 | CA12 (0.53) | MEN1KMT2AEPHX2CA12CA1 | |
| SCHEMBL13480539 | 0.77 | MEN1 (0.77) | MEN1KMT2AEPHX2MTORFPR2 | |
| SCHEMBL11768336 | 0.75 | MEN1 (0.63) | MEN1KMT2AEPHX2MTORCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | Kent Innovation & Enterprise (GB) | 2023-07-18 | — | — | US | disclosed |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | KENT INNOVATION & ENTERPRISE, UNIVERSITY OF KENT (GB) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701333-B2 | Antibacterial compounds | ARF1, ARL1, TLR1 | MEN1 1300/4885KMT2A 2533/4885EPHX2 2581/4885 |
| US-20210128501-A1 | ANTIBACTERIAL COMPOUNDS | ARF1, ARL1, TLR1 | MEN1 1300/4885KMT2A 2533/4885EPHX2 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.